journal article·2026-07-25

MRI‐Based Quantitative Evaluation of Tumor Ferroptosis Mediated by A Novel Self‐Reducing Nano‐Prodrug

Shuang Liu, Hewen Li, Yuhang Ding, Dengyi Duan, Lin Cao, Kangkang Liu, Wenyi Zhang, Shifeng Cheng, Yiming Li, Yunfei Guo, Xiang Qi, Jianmin Li, Xuening Zhang, Jing Peng, Gang Han, Yang Zhao

Publisher page

Abstract

ABSTRACT Ferroptosis is triggered by iron‐dependent lipid peroxidation, which shows great potential in tumor therapy. However, its biomedical applications are constrained by suboptimal therapeutic efficacy, leakage of metal ions from inducing agents, and the absence of noninvasive evaluation methods. In this study, we aimed to develop a self‐reducing nano‐theranostic agent (Fe@AP‐SAS/RGD, FASR) for tumor‐targeted ferroptosis therapy and conducted real‐time magnetic resonance imaging(MRI) to monitor ferroptosis by encapsulating iron oxide particles in natural apple pectin (AP). In a weakly acidic tumor microenvironment, the strong reducing ability of AP accelerated the transformation of Fe 3+ within FASR into highly active Fe 2+ . Subsequently, the concentration of Fe 2+ increased and boosted the antitumor effect of ferroptosis. Notably, MRI of prostate cancer mouse models after intravenous injection of FASR NPs at varying doses revealed that the T 2 value decreased at the tumor sites and exhibited a linear correlation with the changes in ferroptosis hallmark markers, tumor weight, and volume after treatment. These findings demonstrate the capacity of T 2 mapping to quantitatively evaluate ferroptosis efficacy. This study not only introduced a tumor‐targeted and self‐reducing strategy to amplify ferroptosis but also pioneered a novel pathway for noninvasive imaging and monitoring of ferroptosis treatment processes within live tumors.
Source: crossref · Quality: baseline

Affiliations

Department of Radiology The Second Hospital of Tianjin Medical University Tianjin People's Republic of China

Tianjin Institute of Urology The Second Hospital of Tianjin Medical University Tianjin People's Republic of China

Department of Biochemistry and Molecular Biotechnology University of Massachusetts Chan Medical School Worcester Massachusetts USA

Funding

National Natural Science Foundation of China · Natural Science Foundation of Tianjin Municipality · Science Fund for Distinguished Young Scholars of Tianjin Municipality

References (48)

Show source-provided references
1. 10.1002/adma.20210700910.1002/adma.202107009 ↗
2. A Sonication‐Activated Valence‐Variable Sono‐Sensitizer/Catalyst for Autography Inhibition/Ferroptosis‐Induced Tumor Nanotherapy10.1002/anie.202212021 ↗
3. 10.1016/j.jconrel.2022.09.05110.1016/j.jconrel.2022.09.051 ↗
4. 10.1039/D1CS01167G10.1039/D1CS01167G ↗
5. 10.1016/j.cell.2022.07.02510.1016/j.cell.2022.07.025 ↗
6. 10.1002/anie.20240377110.1002/anie.202403771 ↗
7. 10.1016/j.actbio.2022.03.03010.1016/j.actbio.2022.03.030 ↗
8. 10.1039/D0TB01175D10.1039/D0TB01175D ↗
9. 10.1016/j.jconrel.2019.07.02910.1016/j.jconrel.2019.07.029 ↗
10. 10.1002/adma.20200506210.1002/adma.202005062 ↗
11. 10.1186/s12951‐019‐0501‐310.1186/s12951‐019‐0501‐3 ↗
12. 10.1016/j.jconrel.2023.12.05610.1016/j.jconrel.2023.12.056 ↗
13. 10.1016/j.jcis.2023.12.00610.1016/j.jcis.2023.12.006 ↗
14. 10.1016/j.biomaterials.2024.12293510.1016/j.biomaterials.2024.122935 ↗
15. 10.1002/anie.20201687210.1002/anie.202016872 ↗
16. 10.1038/s41568‐022‐00459‐010.1038/s41568‐022‐00459‐0 ↗
17. 10.1038/s41580‐020‐00324‐810.1038/s41580‐020‐00324‐8 ↗
18. 10.1002/smll.20220170410.1002/smll.202201704 ↗
19. 10.1146/annurev‐nutr‐082117‐05173210.1146/annurev‐nutr‐082117‐051732 ↗
20. 10.1016/j.celrep.2020.02.04910.1016/j.celrep.2020.02.049 ↗
21. 10.1039/C8MT00212F10.1039/C8MT00212F ↗
22. 10.1002/anie.20180840010.1002/anie.201808400 ↗
23. 10.1021/acs.inorgchem.0c0141210.1021/acs.inorgchem.0c01412 ↗
24. 10.1021/acssensors.0c0201510.1021/acssensors.0c02015 ↗
25. 10.1021/jacs.0c0670910.1021/jacs.0c06709 ↗
26. 10.1021/jacs.8b0146210.1021/jacs.8b01462 ↗
27. 10.1021/cr100111310.1021/cr1001113 ↗
28. 10.1002/anie.20201441510.1002/anie.202014415 ↗
29. 10.1002/advs.20230946410.1002/advs.202309464 ↗
30. 10.1002/adma.20210900410.1002/adma.202109004 ↗
31. 10.1021/acsnano.1c0426310.1021/acsnano.1c04263 ↗
32. 10.1021/acsnano.1c0188910.1021/acsnano.1c01889 ↗
33. 10.1148/radiol.22206110.1148/radiol.222061 ↗
34. 10.1016/j.cis.2024.10316610.1016/j.cis.2024.103166 ↗
35. 10.3390/molecules2605143410.3390/molecules26051434 ↗
36. 10.1016/j.foodhyd.2020.10611410.1016/j.foodhyd.2020.106114 ↗
37. 10.1016/j.carres.2019.10775210.1016/j.carres.2019.107752 ↗
38. 10.1016/j.jff.2017.10.02810.1016/j.jff.2017.10.028 ↗
39. 10.1016/j.foodhyd.2013.12.00310.1016/j.foodhyd.2013.12.003 ↗
40. 10.1016/j.biopha.2021.11156610.1016/j.biopha.2021.111566 ↗
41. 10.1016/j.ijbiomac.2024.13442510.1016/j.ijbiomac.2024.134425 ↗
42. 10.1016/j.actbio.2025.01.00310.1016/j.actbio.2025.01.003 ↗
43. 10.1002/chem.20230433710.1002/chem.202304337 ↗
44. Multifunctional Nanomaterials for Ferroptotic Cancer Therapy10.3389/fchem.2022.868630 ↗
45. 10.1002/smll.20240429910.1002/smll.202404299 ↗
46. 10.1016/j.phymed.2024.15611510.1016/j.phymed.2024.156115 ↗
47. 10.1039/D2NA00719C10.1039/D2NA00719C ↗
48. 10.1016/j.chempr.2022.03.00910.1016/j.chempr.2022.03.009 ↗